claudio arrechedera

Research Scientist at UT MD Anderson Cancer Center “#sehablaespanol”

[claudio arrechedera @claudioarpa]

Somos el ejemplo para las nuevas generaciones #motivacion #valores #pensamientopositivo #VenezuelaDeOportunidades

[UT MD Anderson @UTMDAnderson]

UT MD Anderson researchers found the YAP1 protein is a potential biomarker and therapeutic target to overcome chemotherapy resistance in patients with small cell lung cancer.

Learn more: https://t.co/h2zIzeYlk6 #EndCancer

[Linghua Wang, MD, PhD @IamLinghua]

Proud to share our @theNCI #HTAN-supported GAME3D team at #AACR26, with 3 talks (@DrMingyaoLi @tae_hwang and me) and 3 posters. We use #Spatial multi-omics, 3D modeling, digital pathology and AI to study #GastricCancer evolution. Learn more about GAME3D: https://t.co/ROZ4Gjm3su

[Oscar Tahuahua @OscarTahuahua]

Radiation oncology is changing fast.

But radiation can still injure normal tissue.
An excellent review in @NEJM explains how modern RadOnc is reducing that risk:

-Precision planning
-Adaptive radiotherapy
-Biologic personalization
-AI-assisted treatment design

the goal is simple: maximize tumor control while protecting normal tissue
https://t.co/Kvj2WKgDKX @OncoAlert

[UT MD Anderson @UTMDAnderson]

MD Anderson researchers found novel tumor suppressor BATF2 can be silenced by factors in the tumor microenvironment, leading to a reduced immune response in five preclinical models of head and neck cancers: https://t.co/68yPgWjf45 #EndCancer

[Pavlos Msaouel @PavlosMsaouel]

@kaydaustin @ERPlimackMD @crisbergerot @NazliDizman @BradMcG04 @g_procopio_ @OncHahn @LabGenovese @salvolarosa @andrewjohnsmd @OAlhalabiMD @perelli_luigi @rahulshethmd @ChadTangMD @TiansterZhang @QingZhangLab @BCottaMD @DrDanielHeng @Daniel_J_George @SGoswamiMDPhD @priyaraomd @UroDocAsh @ChapinMD @drmehrarohit @LisaHenske @ED_PhD_ @DanielFrigo @rovingatuscap @shilpaonc @AmandaNizamMD 5/5 While the trial was “negative” its impact is profound. We have largely stopped using immune checkpoint therapy in RMC outside trials, which in itself has likely saved many lives. Next step: mechanism-guided trials targeting master myeloid regulators to finally bend the curve.

[Pavlos Msaouel @PavlosMsaouel]

@kaydaustin @ERPlimackMD @crisbergerot @NazliDizman @BradMcG04 @g_procopio_ @OncHahn @LabGenovese @salvolarosa @andrewjohnsmd @OAlhalabiMD @perelli_luigi @rahulshethmd @ChadTangMD @TiansterZhang @QingZhangLab @BCottaMD @DrDanielHeng @Daniel_J_George @SGoswamiMDPhD 4/5 Using our immunocompetent somatic-mosaic RMC mouse model, we recapitulated this effect: immune checkpoint therapy accelerated tumor growth & activated myeloid-affiliated transcriptional programs. Pharmacologic p300 blockade shut down this program & restored sensitivity.

[Pavlos Msaouel @PavlosMsaouel]

@kaydaustin @ERPlimackMD @crisbergerot @NazliDizman @BradMcG04 @g_procopio_ @OncHahn @LabGenovese @salvolarosa @andrewjohnsmd 3/5 Why? Single-cell RNA-seq of tumors before/after therapy showed that ICT triggered an IFNγ-driven “myeloid mimicry” program in RMC cells. Tumors switched on CEBPB/p300-regulated myeloid-like circuits that boosted proliferation and fueled hyperprogression instead of immunity.

[Pavlos Msaouel @PavlosMsaouel]

2/5 Clinically, 10 pts with RMC were treated; there were no confirmed responses, median PFS was ~1.4 months, and 5/10 met radiologic criteria for hyperprogression. Thus, for RMC immune checkpoint combination was not just ineffective; it could be harmful.

[Pavlos Msaouel @PavlosMsaouel]

1/5 Our new @NatureComms study reports the first-ever dedicated clinical trial for #RenalMedullaryCarcinoma (RMC): phase II trial of #nivolumab + #ipilimumab and what it taught us about hyperprogression to immunotherapy: https://t.co/q1UwZr8L3i #endRMC #MsaouelLab @MDAndersonNews

[UT MD Anderson @UTMDAnderson]

Some cancer patients at MD Anderson rely on blood and platelet donations as part of their treatment.

If you are able, consider making an appointment to donate blood at the MD Anderson Blood Bank. #WorldBloodDonorDay #EndCancer

[claudio arrechedera @claudioarpa]

Prostate cancer–induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone–tumor microenvironment through Wnt pathway–induced M2 macrophage polarization | PNAS https://t.co/2jVsUm1eeH

[UT MD Anderson @UTMDAnderson]

Thanks to a generous $150 million gift from Kinder Foundation, we announce the launch of Kinder Children’s Cancer Center. This joint venture of UT MD Anderson and @TexasChildrens has a single mission: to #EndChildhoodCancer. https://t.co/QFBRpX3KKp #UTMDAnderson_TexasChildrens

[Cancer Cell @Cancer_Cell]

Online Now: Spatial and multiomics analysis of human and mouse lung adenocarcinoma precursors reveals TIM-3 as a putative target for precancer interception https://t.co/AcqAnCyQln

[Peter WT Pisters, MD @ppisters]

Headed back to HTX from Chicago and this is what I saw at @fly2ohare. The most powerful brand in cancer care - the global leader:

[Yüksel Ürün @DrYukselUrun]

Abstracts Open for #KCRS25
Are you shaping the future of kidney cancer care? 🔬🧬
Submit your research to the 2025 Kidney Cancer Research Summit!
LINK:
https://t.co/Gr4PYVaUwR

@kidneycan @IKCCorg @DrChoueiri @HHammersMD @DrRanaMcKay

[Cancer Cell @Cancer_Cell]

Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy https://t.co/0N1e7m0VBo

[Eric K. Singhi, MD @lungoncdoc]

Great morning back at #AcademicTuesday, lecturing our @MDAndersonNews oncology fellows on stage IV lung cancer management!

We discussed how to sequence therapies, the importance of shared decision-making, & the value of patient support. Thanks @KelseyPanMD for the invite!

[Cancer Cell @Cancer_Cell]

Online Now: Hypoxia inducible factor-1α drives cancer resistance to cuproptosis https://t.co/ED0axZWvu1

[claudio arrechedera @claudioarpa]

https://t.co/zmi3vxJ21h

[claudio arrechedera @claudioarpa]

https://t.co/zmi3vxJzQP